S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

Inclusion criteria

DISEASE CHARACTERISTICS: * Biopsy-proven\* bronchioloalveolar carcinoma (BAC) or BAC variants (e.g., adenocarcinoma with BAC features, BAC with invasive adenocarcinoma) meeting the following criteria: * Incompletely resected or unresectable disease * No component of squamous cell carcinoma * Disease staged as 1 of the following: * Stage IIIB disease (T4 \[cytologically confirmed malignant pleural effusion OR pleural tumor foci that are separate from direct pleural invasion by the primary tumor\], any N, M0) * Stage IV disease (any T, any N, M1 \[distant metastases present\]) * Recurrent disease in a separate lobe after prior resection within the past 5 years; multifocal lesions in \> 1 lobe; or any disease that is recurrent after surgery or radiotherapy is considered stage IV disease * Tumor may be multifocal or diffuse NOTE: \*Cytology specimens, including bronchial brushing, washings, or fine needle aspiration specimens, alone are not acceptable for diagnosis * Measurable or nonmeasurable disease by chest CT scan * Pleural effusions, ascites, and laboratory parameters are not acceptable as only evidence of disease * Disease must be present outside field of prior radiotherapy OR a new lesion must be inside port * Treated brain metastases allowed provided the patient is asymptomatic and do not require steroids PATIENT CHARACTERISTICS: * Zubrod performance status 0-2 * Absolute neutrophil count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Total bilirubin normal * AST or AST ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present) * Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN if bone metastases are present) * Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 50 mL/min * Urine protein:creatinine ratio ≤ 0.5 OR urine protein \< 1 g by 24-hour urine collection * Willing to provide prior smoking history * No hemoptysis ≥ ½ teaspoon within the past 28 days * No clinical history of pulmonary or upper respiratory hemorrhage \> grade 2 within the past 6 months or \> grade 1 within the past 28 days * No history of thromboses or hemorrhage, including hemorrhagic or thrombotic stroke, or other CNS bleeding * No uncontrolled hypertension * No serious nonhealing wound, ulcer, or bone fracture * No other prior malignancy except for any of the following: * Adequately treated basal cell or squamous cell skin cancer * In situ cervical cancer * Adequately treated stage I or II cancer that is currently in complete remission * Any other cancer from which the patient has been disease free for 5 years * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Recovered from prior therapy * At least 28 days since prior radiotherapy (14 days for palliative radiotherapy) * At least 28 days since prior surgery (thoracic or other major surgeries) * More than 7 days since prior fine-needle aspiration or core biopsy * At least 28 days since prior systemic chemotherapy or biologic therapy * No prior gefitinib hydrochloride, erlotinib hydrochloride, or bevacizumab * No other prior anti-epidermal growth factor receptor or anti-vascular endothelial growth factor therapies * Concurrent stable, therapeutic anticoagulation therapy allowed (i.e., warfarin or low molecular weight heparin), provided the patient has no history of bleeding complications on anticoagulation or an inability to establish a stable therapeutic regimen for anticoagulation * No other concurrent anticancer therapy, including surgery, chemotherapy, hormone therapy, biologic therapy, or radiotherapy